预约演示
更新于：2025-03-01
Eperisone Hydrochloride
盐酸乙哌立松
更新于：2025-03-01
概要
基本信息
原研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H26ClNO |
InChIKeyGTAXGNCCEYZRII-UHFFFAOYSA-N |
CAS号56839-43-1 |
关联
31
项与 盐酸乙哌立松 相关的临床试验CTR20244465
盐酸乙哌立松片餐后生物等效性试验
CTR20244466
盐酸乙哌立松片空腹生物等效性试验
CTR20244351
盐酸乙哌立松片在空腹及餐后条件下的人体生物等效性试验
100 项与 盐酸乙哌立松 相关的临床结果
登录后查看更多信息
100 项与 盐酸乙哌立松 相关的转化医学
登录后查看更多信息
100 项与 盐酸乙哌立松 相关的专利（医药）
登录后查看更多信息
257
项与 盐酸乙哌立松 相关的文献（医药）2025-02-19POSTGRADUATE MEDICAL JOURNAL
Comparative effect of oral drugs in improving spasticity of different etiology: a network meta-analysis
Article
作者: López-López, Samuel ; Cavero-Redondo, Iván ; Saz-Lara, Alicia ; Martínez-Rodrigo, Arturo ; Moreno-Herráiz, Nerea ; Otero-Luis, Iris
Abstract:
Introduction:
Spasticity, a prevalent manifestation of various neurological conditions, significantly impacts the quality of life of patients. Research on the effects of oral drugs on spasticity has produced controversial results. Thus, the aim of this network meta-analysis was to compare the efficacy of oral drugs for improving spasticity in patients with different etiologies.
Methods:
We searched four different databases from their inception to 30 November 2023. A network meta-analysis using a frequentist perspective was conducted to assess the effects of different oral drugs on spasticity, evaluated by the modified Ashworth scale.
Results:
Our findings showed that, in a frequentist network meta-analysis, eperisone, diazepam, and baclofen had significantly greater spasticity, as measured by the modified Ashworth scale, than did the placebo (MD: −0.80; 95% CIs: −1.42, −0.18; MD: −0.68; 95% CIs: −1.28, −0.09; MD: −0.58; 95% CIs: −1.11, −0.06, respectively).
Conclusion:
In summary, our study confirmed that eperisone, diazepam, and baclofen could be effective approaches for reducing spasticity of different etiologies and could be useful approaches for improving patient quality of life.Key messages What is already known on this topic: The impact of oral drugs, such as baclofen, gabapentin, tizanidine, and dantrolene, in the treatment of spasticity has been documented. What this study adds: This study determines which of the oral drugs aimed at treating spasticity is the most effective across different etiologies. How this study might affect research, practice, or policy: This study suggests tailored treatment strategies for spasticity based on its etiology.
2025-01-01MICROCHEMICAL JOURNAL
Green analytical comparison and central composite design optimization for simultaneous estimation of pain management drugs using RP-liquid chromatography
作者: Awadh, Mohammed Al ; Bhavitha, K. ; Meenakshi, V. ; Harani, A. ; Kumar, D. Sathis ; Yuheng, Lu ; Prasad, N. E. Chandra ; Lee, It Ee ; Rajendran, Parvathy
The Central Composite Design method was utilized to validate a precise RP-HPLC method for concurrently determining the quantities of Paracetamol (PC), Diclofenac Sodium (DS), and Eperisone Hydrochloride (EH) in tablet compositionsBy employing Design of Experiment (DOE), the exptl. parameters were fine-tuned, resulting in an optimized eluent consisting of methanol: water (90:10) with 0.1% orthophosphoic acid at a eluent velocity of 1 mL/min.The method exhibited exceptional purities: PC (100.83% ± 0.85), DS (102.01% ± 0.90), and EH (100.49% ± 1.29).Regression equations were formulated for PC, DS, and EH as follows: y = 479762x + 151907, y = 2182788x + 2409442, and y = 777144x - 1146334, resp.The anal. method underwent comprehensive validation, including tests for: Accuracy, Precision, Linearity and Robustness.To assess the method's environmental impact, several Green Anal. Chem. (GAC) tools were employed.These tools provided a multifaceted evaluation of the method's sustainability and eco-friendliness.
2024-03-30Chemical & pharmaceutical bulletin
Eperisone Hydrochloride, a Muscle Relaxant, Is a Potent P2X7 Receptor Antagonist
Article
作者: Nose, Takashi ; Okada, Makoto
Eperisone Hydrochloride was launched in Japan in 1983 and has been used to improve muscle tone and treat spastic paralysis (Originator: Eisai Co., Ltd.). However, its biochemical mechanism of action is unknown. SB Drug Discovery was used to evaluate purinergic P2X (P2X) receptor antagonism using fluorescence. In this study, we discovered that its target protein is the P2X7 receptor. Also, P2X receptor subtype selectivity was high. This finding demonstrates the (Eperisone-P2X7-pain linkage), the validity of P2X7 as a drug target, and the possibility of drug repositioning of Eperisone Hydrochloride.
100 项与 盐酸乙哌立松 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肌张力亢进 | 日本 | 2014-05-16 | |
| 痉挛性麻痹 | 日本 | 2014-05-16 | |
| 肌肉痉挛 | - | - | - |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性腰痛 | 临床3期 | - | 2014-03-01 | |
| 椎间盘疾病 | 临床3期 | - | 2014-03-01 | |
| 腰痛 | 临床3期 | 印度 | 2006-04-01 | |
| 痉挛 | 临床3期 | 印度 | 2006-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用